About Novan
Novan is a company based in Morrisville (United States) founded in 2006. Novan has raised $164.84 million across 30 funding rounds from investors including NIH, HHS and Ligand Pharmaceuticals. The company has 89 employees as of December 31, 2022. Novan has completed 1 acquisition, including EPI Health. Novan offers products and services including ZELSUVMI, SB204, and NITRICIL. Novan operates in a competitive market with competitors including Incyte, LEO Pharma, Formation Bio, Arcutis and Inovio Pharmaceuticals, among others.
- Headquarter Morrisville, United States
- Employees 89 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novan, Inc.
-
Annual Revenue
$23.68 M (USD)701as on Dec 31, 2022
-
Net Profit
-$31.31 M (USD)-5as on Dec 31, 2022
-
EBITDA
-$34.23 M (USD)-14as on Dec 31, 2022
-
Total Equity Funding
$164.84 M (USD)
in 30 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Jul 22, 2020
-
Investors
NIH
& 8 more
-
Employee Count
89
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novan
Novan offers a comprehensive portfolio of products and services, including ZELSUVMI, SB204, and NITRICIL.
Treatment for molluscum contagiosum skin infection
Nitric oxide-based therapy for skin conditions
Innovative nitric oxide technology for dermatological treatments
People of Novan
Unlock access to complete
Unlock access to complete
Funding Insights of Novan
Novan has successfully raised a total of $164.84M across 30 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novan
Novan has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, HHS and Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Novan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novan
Novan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EPI Health.
Investment portfolio details for Novan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Innovative therapeutic treatments for skin diseases are developed.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Novan
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novan
Detailed financials for Novan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novan Comparisons
Peer comparison for Novan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novan
Novan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Incyte, LEO Pharma, Formation Bio, Arcutis and Inovio Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutic solutions for dermatological conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for the treatment of cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
Detailed competitors of Novan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novan
Complete news archive for Novan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novan
Novan was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Novan is headquartered in Morrisville, United States.
Paula Brown Stafford is the current CEO of Novan.
Novan is a funded company, having raised a total of $164.84M across 30 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Novan is 89.
Annual revenue of Novan is $23.68M as on Dec 31, 2022.
Novan was founded in 2006 and is headquartered in Morrisville, United States. Therapeutics based on nitric oxide are developed by the company for various dermatology conditions. The proprietary Nitricil platform is utilized to create novel nitric oxide-based new chemical entities for topical applications. A lead candidate targets acne vulgaris, while other programs address human papillomavirus infections, onychomycosis, psoriasis, and atopic dermatitis.
Novan's top competitors include LEO Pharma, Formation Bio and Arcutis.
Novan offers ZELSUVMI, SB204, and NITRICIL.
Novan has made 1 acquisition, including EPI Health.
Novan has 9 investors. Key investors include NIH, HHS, Ligand Pharmaceuticals, Aspire Capital, and U.S. Department of Defense.